|
1.
|
Erdem NF, Carlson ER, Gerard DA and Ichiki
AT: Characterization of 3 oral squamous cell carcinoma cell lines
with different invasion and/or metastatic potentials. J Oral
Maxillofac Surg. 65:1725–1733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Exarchos KP, Goletsis Y and Fotiadis DI: A
multiscale and multiparametric approach for modeling the
progression of oral cancer. BMC Med Inform Decis Mak. 12:1362012.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Tanaka T, Tanaka M and Tanaka T: Oral
carcinogenesis and oral cancer chemoprevention: a review. Patholog
Res Int. 2011:4312462011.PubMed/NCBI
|
|
4.
|
Garg P and Karjodkar F: ‘Catch them before
it becomes too late’ - oral cancer detection. Report of two cases
and review of diagnostic AIDS in cancer detection. Int J Prev Med.
3:737–741. 2012.
|
|
5.
|
Wise-Draper TM, Draper DJ, Gutkind JS,
Molinolo AA, Wikenheiser-Brokamp KA and Wells SI: Future directions
and treatment strategies for head and neck squamous cell
carcinomas. Transl Res. 160:167–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Sawicki M, Szudy A, Szczyrek M, Krawczyk P
and Klatka J: Molecularly targeted therapies in head and neck
cancers. Otolaryngol Pol. 66:307–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Cripps C, Winquist E, Devries MC,
Stys-Norman D and Gilbert R; Head and Neck Cancer Disease Site
Group: Epidermal growth factor receptor targeted therapy in stages
III and IV head and neck cancer. Cur Oncol. 17:37–48.
2010.PubMed/NCBI
|
|
8.
|
Tahara M, Minami H, Kawashima M, Kawada K,
Mukai H, Sakuraba M, Matsuura K, Takashi O, Hayashi R and Ohtsu A:
Phase I trial of chemoradiotherapy with the combination of S-1 plus
cisplatin for patients with unresectable locally advanced squamous
cell carcinoma of the head and neck. Cancer Sci. 102:419–424. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Ogata Y, Sasatomi T, Akagi Y, Ishibashi N,
Mori S and Shirouzu K: Dosage escalation study of S-1 and
irinotecan in metronomic chemotherapy against advanced colorectal
cancer. Kurume Med J. 56:1–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ooyama A, Oka T, Zhao H, Yamamoto M,
Akiyama S and Fukushima M: Anti-angiogenic effect of
5-Fluorouracil-based drugs against human colon cancer xenografts.
Cancer Lett. 267:26–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Tsukuda M, Kida A, Fujii M, Kono N,
Yoshihara T, Hasegawa Y and Sugita M; Chemotherapy Study Group of
Head and Neck Cancer: Randomized scheduling feasibility study of
S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br
J Cancer. 93:884–889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Tsukuda M, Ishitoya J, Mikami Y, Matsuda
H, Horiuchi C, Taguchi T, Satake K, Kawano T, Takahashi M,
Nishimura G, Kawakami M, Sakuma Y, Watanabe M, Shiono O, Komatsu M
and Yamashita Y: Analysis of feasibility and toxicity of concurrent
chemoradiotherapy with S-1 for locally advanced squamous cell
carcinoma of the head and neck in elderly cases and/or cases with
comorbidity. Cancer Chemother Pharmacol. 64:945–952. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Kuratomi Y, Satoh S, Monji M, Yokogawa K,
Suzuki K, Shimazu R, Tokumaru S and Inokuchi A: A comparative study
of concurrent chemoradiotherapy with S-1 or CDDP for pharyngeal or
laryngeal cancer. Gan To Kagaku Ryoho. 37:1471–1476. 2010.(In
Japanese).
|
|
14.
|
Kubota K, Sato H, Sakaki H, Nakagawa H,
Kon T, Narita N, Kobayashi W and Kimura H: A case of submandibular
gland cancer in elderly patients showed significant effect by S-1
and intravenous docetaxel chemotherapy concurrent with
radiotherapy. Gan To Kagaku Ryoho. 37:1937–1940. 2010.(In
Japanese).
|
|
15.
|
Abu Lila AS, Okadaa T, Doia Y, Ichiharaa
M, Ishidaa T and Kiwadaa H: Combination therapy with metronomic S-1
dosing and oxaliplatin-containing PEG-coated cationic liposomes in
a murine colorectal tumor model: Synergy or antagonism? Int J
Pharmaceutics. 426:263–270. 2012.
|
|
16.
|
Kerbel R and Kamen B: The anti-angiogenic
basis of metronomic chemotherapy. Nat Rev Cancer. 4:423–436. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Man S, Bocci G, Francia G, Green SK, Jothy
S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G and Kerbel RS:
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide
administered continuously through the drinking water. Cancer Res.
62:2731–2735. 2002.PubMed/NCBI
|
|
18.
|
Doi Y, Okada T, Matsumoto H, Ichihara M,
Ishida T and Kiwada H: Combination therapy of metronomic S-1 dosing
with oxaliplatin-containing polyethylene glycol-coated liposome
improves antitumor activity in a murine colorectal tumor model.
Cancer Sci. 101:2470–2475. 2010. View Article : Google Scholar
|
|
19.
|
Iwamoto H, Torimura T, Nakamura T,
Hashimoto O, Inoue K, Kurogi J, Niizeki T, Kuwahara R, Abe M, Koga
H, Yano H, Kerbel RS, Ueno T and Sata M: Metronomic S-1
chemotherapy and vandetanib: an efficacious and nontoxic treatment
for hepatocellular carcinoma. Neoplasia. 13:187–197.
2011.PubMed/NCBI
|
|
20.
|
Munoz R, Shaked Y, Bertolinic F,
Emmenegger U, Man S and Kerbel RS: Anti-angiogenic treatment of
breast cancer using metronomic low-dose chemotherapy. Breast.
14:466–479. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Munoz R, Man S, Shaked Y, Lee CR, Wong J,
Francia G and Kerbel RS: Highly efficacious nontoxic preclinical
treatment for advanced metastatic breast cancer using combination
oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res.
66:3386–3391. 2006. View Article : Google Scholar
|
|
22.
|
Allegrini G, Di Desidero T, Barletta MT,
Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo
A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A,
Brandi G, Danesi R, Kerbel RS, Falcone A and Bocci G: Clinical,
pharmacokinetic and pharmacodynamic evaluations of metronomic UFT
and cyclophosphamide plus celecoxib in patients with advanced
refractory gastrointestinal cancers. Angiogenesis. 15:275–286.
2012. View Article : Google Scholar
|
|
23.
|
Kerbel RS: Improving conventional or low
dose metronomic chemotherapy with targeted antiangiogenic drugs.
Cancer Res Treat. 39:150–159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Kato H, Ichinose Y and Ohta M, Hata E,
Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and
Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant
Chemotherapy: A randomized trial of adjuvant chemotherapy with
uracil-tegafur for adenocarcinoma of the lung. N Engl J Med.
350:1713–1721. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Caballero M, Grau JJ, Blanch JL,
Domingo-Domenech J, Auge JM, Jimenez W and Bernal-Sprekelsen M:
Serum vascular endothelial growth factor as a predictive factor in
metronomic (weekly) paclitaxel treatment for advanced head and neck
cancer. Arch Otolaryngol Head Neck Surg. 133:1143–1148. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Patil V, Noronha V, D’cruz AK, Banavali SD
and Prabhash K: Metronomic chemotherapy in advanced oral cancers. J
Cancer Res Ther. 8:106–110. 2012.
|
|
27.
|
Hollemann D, Yanagida G, Rüger BM,
Neuchrist C and Fischer MB: New vessel formation in peritumoral
area of squamous cell carcinoma of the head and neck. Head Neck.
34:813–820. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Shaked Y, Emmenegger U, Man S, Cervi D,
Bertolini F, Ben-David Y and Kerbel RS: Optimal biologic dose of
metronomic chemotherapy regimens is associated with maximum
antiangiogenic activity. Blood. 106:3058–3061. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Bertolini F, Paul S, Mancuso P,
Monestiroli S, Gobbi A, Shaked Y and Kerbel RS: Maximum tolerable
dose and low-dose metronomic chemotherapy have opposite effects on
the mobilization and viability of circulating endothelial
progenitor cells. Cancer Res. 63:4342–4346. 2003.PubMed/NCBI
|
|
30.
|
Loven D, Hasnis E, Bertolini F and Shaked
Y: Low-dose metronomic chemotherapy: from past experience to new
paradigms in the treatment of cancer. Drug Discov Today.
18:193–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Christopoulos A, Ahn SM, Klein JD and Kim
S: Biology of vascular endothelial growth factor and its receptors
in head and neck cancer: Beyond angiogenesis. Head Neck.
33:1220–1229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Hamano Y, Sugimoto H, Soubasakos MA,
Kieran M, Olsen BR, Lawler J, Sudhakar A and Kalluri R:
Thrombospondin-1 associated with tumor microenvironment contributes
to low-dose cyclophosphamide-mediated endothelial cell apoptosis
and tumor growth suppression. Cancer Res. 64:1570–1574. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Kundumani-Sridharan V, Niu J, Wang D, Van
Quyen D, Zhang Q, Singh NK, Subramani J, Karri S and Rao GN:
15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires
Src-mediated Egr-1-dependent rapid induction of FGF-2 expression.
Blood. 115:2105–2116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Shimoyamada H, Yazawa T, Sato H, Okudela
K, Ishii J, Sakaeda M, Kashiwagi K, Suzuki T, Mitsui H, Woo T,
Tajiri M, Ohmori T, Ogura T, Masuda M, Oshiro H and Kitamura H:
Early growth response-1 induces and enhances vascular endothelial
growth factor-A expression in lung cancer cells. Am J Pathol.
177:70–83. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Bocci G, Francia G, Man S, Lawler J and
Kerbel RS: Thrombospondin 1, a mediator of the antiangiogenic
effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci.
100:12917–12922. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Rastogi P: Emergence of cancer stem cells
in head and neck squamous cell carcinoma: a therapeutic insight
with literature review. Dent Res J (Isfahan). 9:239–244.
2012.PubMed/NCBI
|
|
37.
|
Loges S, Schmidt T and Carmeliet P:
Mechanisms of resistance to anti-angiogenic therapy and development
of third-generation anti-angiogenic drug candidates. Genes Cancer.
1:12–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Sayed SI, Dwivedi RC, Katna R, Garg A,
Pathak KA, Nutting CM, Rhys-Evans P, Harrington KJ and Kazi R:
Implications of understanding cancer stem cell (CSC) biology in
head and neck squamous cell cancer. Oral Oncol. 47:237–243. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Kokko LL, Hurme S, Maula SM, Alanen K,
Grénman R, Kinnunen I and Ventelä S: Significance of site-specific
prognosis of cancer stem cell marker CD44 in head and neck
squamous-cell carcinoma. Oral Oncol. 47:510–516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Prince ME, Sivanandan R, Kaczorowski A,
Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles
LE: Identification of a subpopulation of cells with cancer stem
cell properties in head and neck squamous cell carcinoma. Proc Natl
Acad Sci. 104:973–978. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Wang W, Lin P, Han C, Cail W, Zhao X and
Sun B: Vasculogenic mimicry contributes to lymph node metastasis of
laryngeal squamous cell carcinoma. J Exp Clin Cancer Res.
29:602010. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Dales JP, Garcia S, Carpentier S, Andrac
L, Ramuz O, Lavaut MN, Allasia C, Bonnier P and Charpin C:
Long-term prognostic significance of neoangiogenesis in breast
carcinomas: comparison of Tie-2/Tek, CD105, and CD31
immunocytochemical expression. Hum Pathol. 35:176–183. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Kerbel RS: Inhibition of tumor
angiogenesis as a strategy to circumvent acquired resistance to
anti-cancer therapeutic agents. Bioessays. 13:31–36. 1991.
View Article : Google Scholar
|
|
44.
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Harada K, Kawaguchi S, Supriatno,
Kawashima Y, Yoshida H and Sato M: S-1, an oral fluoropyrimidine
anti-cancer agent, enhanced radiosensitivity in a human oral cancer
cell line in vivo and in vitro: involvement possibility of
inhibition of survival signal, Akt/PKB. Cancer Lett. 226:161–168.
2005. View Article : Google Scholar
|
|
46.
|
Harada K, Kawaguchi S, Supriatno, Onoue T,
Yoshida H and Sato M: Enhancement of apoptosis in salivary gland
cancer cells by the combination of oral fluoropyrimidine anticancer
agent (S-1) and radiation. Int J Oncol. 25:905–911. 2004.PubMed/NCBI
|
|
47.
|
Zhao HY, Ooyama A, Yamamoto M, Ikeda R,
Haraguchi M, Tabata S, Furukawa T, Che XF, Zhang S, Oka T,
Fukushima M, Nakagawa M, Ono M, Kuwano M and Akiyama S: Molecular
basis for the induction of an angiogenesis inhibitor,
thrombospondin-1, by 5-fluorouracil. Cancer Res. 68:7035–7041.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Bancroft CC, Chen Z, Dong G, Sunwoo JB,
Yeh N, Park C and Van Waes C: Coexpression of proangiogenic factors
IL-8 and VEGF by human head and neck squamous cell carcinoma
involves coactivation by MEK-MAPK and IKK-NF-kappaB signal
pathways. Clin Cancer Res. 7:435–442. 2001.PubMed/NCBI
|
|
49.
|
Motegi K, Azuma M, Aota K, Yamashita T,
Tamatani T, Harada K, Yoshida H and Sato M: Effect of a mutant form
of IkappaB-alpha on 5-fluorouracil-induced apoptosis in transformed
human salivary gland cells. Oral Oncol. 37:185–192. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Harada K, Supriatno, Kawashima Y, Yoshida
H and Sato M: S-1 inhibits tumorigenicity and angiogenesis of human
oral squamous cell carcinoma cells by suppressing expression of
phosphorylated Akt, vascular endothelial growth factor and
fibroblast growth factor-2. Int J Oncol. 30:365–374. 2007.
|
|
51.
|
Lévi F: Circadian chronotherapy for human
cancers. Lancet Oncol. 2:307–315. 2001.
|
